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Abstract 
Background: Selenoprotein S (SelS) is a transmembrane protein that is expressed in the liver, skeletal muscle, 
adipose tissue, pancreatic islets, kidney, and blood vessels. In addition to its transmembrane localization, SelS is also 
secreted from hepatoma HepG2 cells (but not L6 skeletal muscle cells, 3T3‑L1 adipocytes, Min6 pancreatic β cells and 
human embryonic kidney 293 cells) and has been detected in the serum of some human subjects, with a detec‑
tion rate of 31.1 %. These findings prove that serum SelS is secreted by hepatocytes. However, whether vascularly 
expressed SelS can be secreted has not been reported. Transmembrane SelS has been suggested to play different 
roles in the pathogenesis and progression of diabetes mellitus (DM) and atherosclerosis (AS), but the association of 
secreted SelS with DM and macroangiopathy remains unclear.
Research design and methods: Supernatants were collected from human umbilical vein endothelial cells (HUVECs), 
human aortic vascular smooth muscle cells (HA/VSMCs) and human hepatoma HepG2 cells that were untransfected 
or transfected with the indicated plasmid and concentrated for western blotting. Serum samples were collected 
from 158 human subjects with or without type 2 DM (T2DM) and/or AS. Serum SelS levels were measured using an 
enzyme‑linked immunosorbent assay.
Results: Secreted SelS was only detected in the supernatants of hepatoma HepG2 cells. The SelS detection rate 
among the 158 human serum samples was 100 %, and the average SelS level was 64.81 ng/dl. The serum SelS level in 
the isolated DM subjects was lower than the level in the healthy control subjects (52.66 ± 20.53 vs 70.40 ± 21.38 ng/
dl). The serum SelS levels in the DM complicated with SAS subjects (67.73 ± 21.41 ng/dl) and AS subjects 
(71.69 ± 27.00 ng/dl) were significantly increased compared with the serum SelS level in the isolated DM subjects. 
There was a positive interaction effect between T2DM and AS on the serum SelS level (P = 0.002). Spearman correla‑
tion analysis showed that the serum SelS level was negatively correlated with fasting plasma glucose.
Conclusions: Vascular endothelial and vascular smooth muscle cells could not secrete SelS. Serum SelS was primarily 
secreted by hepatocytes. SelS was universally detected in human serum samples, and the serum SelS level was associ‑
ated with T2DM and its macrovascular complications. Thus, regulating liver and serum SelS levels might become a 
new strategy for the prevention and treatment of DM and its macrovascular complications.
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Background
Selenoprotein S (SelS, also known as Tanis, SEPS1 and 
VIMP) is a 21  kDa transmembrane protein with an 
extensive histological distribution. SelS is expressed in 
the liver, skeletal muscle, adipose tissue, pancreatic islets, 
kidney and blood vessels [1–6]. Studies have shown that 
SelS is closely associated with inflammation, oxidative 
stress and endoplasmic stress. It acts as a receptor for the 
acute phase inflammatory response protein serum amy-
loid A [2], and a NF-κB binding site is located within the 
SelS gene promoter region [4]. Moreover, SelS can regu-
late the production of inflammatory factors such as IL-1β 
and IL-6 [7]. SelS is a thioredoxin-dependent reductase 
that can reduce its substrate hydrogen peroxide (H2O2) 
or other peroxidases and combat the reactive oxygen spe-
cies produced during the oxidative stress reaction [8]. 
Furthermore, SelS participates in the endoplasmic retic-
ulum (ER)-associated protein degradation pathway by 
forming a complex with Derlin-1, ubiquitin ligase E3, p97 
ATPase and selenoprotein K; this complex is responsible 
for the degradation of unfolded or misfolded proteins [9, 
10].
The above biological characteristics of SelS suggest 
that it plays roles in the pathogenesis and development 
of diabetes mellitus (DM) and atherosclerosis (AS). Wal-
der et al. [2] reported that hepatic SelS expression in the 
Psammomys obesus, a polygenic animal model of type 2 
diabetes and metabolic syndrome, with impaired glucose 
tolerance and type 2 DM (T2DM) was lower than expres-
sion in Psammomys obesus with normal glucose toler-
ance. Hepatic SelS expression was inversely correlated 
with the circulating glucose and insulin levels. These 
authors found that SelS overexpression in hepatoma 
H4IIE cells reduced basal and insulin-stimulated glucose 
uptake, glycogen synthesis and glycogen content in vitro 
[11]. Furthermore, Walder et  al. [2] showed that SelS 
expression in cultured C2C12 muscle cells and 3T3-L1 
adipocytes was inhibited by glucose and insulin in a dose-
dependent manner. However, Gao et al. [3] found that the 
overexpression of SelS in Min6 pancreatic β cells in pan-
creatic islets increased their resistance to H2O2-induced 
injury and increased their cell viability. In a clinical study, 
Karlsson et  al. [12] analyzed SelS mRNA expression in 
the subcutaneous adipose tissues of T2DM patients and 
healthy individuals matched for age and body weight and 
found that the SelS mRNA in the subcutaneous adipose 
tissues of T2DM patients was significantly increased after 
hyperinsulinemic-euglycemic clamp experiments; in con-
trast, no significant change in expression was detected in 
the healthy control group. Subsequently, our group ana-
lyzed SelS mRNA expression in omental adipose tissues 
from T2DM patients and non-T2DM individuals and 
showed that SelS expression in these tissues was higher 
in T2DM patients than that in non-DM individuals and 
was positively correlated with the insulin resistance index 
[13]. The above studies indicated that membrane SelS 
was closely associated with the body glucose metabolic 
process. Briefly, SelS expression in the liver, adipose tis-
sue, and skeletal muscle promoted the pathogenesis and 
development of DM and insulin resistance, whereas 
overexpression of SelS in pancreatic islets protected pan-
creatic islet β cells from oxidative stress-induced injury. 
Studies of SelS expression in blood vessels have also been 
recently reported. Our group showed that SelS overex-
pression protected human umbilical vein endothelial 
cells (HUVECs) from H2O2-induced injury [5]. Ye et  al. 
[6] reported that the inhibition of SelS expression in pri-
mary vascular smooth muscle cells (VSMCs) increased 
H2O2- or tunicamycin-induced apoptosis. In conclusion, 
transmembrane SelS is closely associated with DM and 
AS and has advantageous and disadvantageous effects in 
different tissues and organs.
In addition to SelS transmembrane localization, Gao 
et al. [1] first detected secreted SelS in the culture media 
of hepatoma HepG2 cells and the serum of some human 
subjects, with a detection rate of 31.1  %. SelS secretion 
has not been detected in the supernatants of L6 skeletal 
muscle cells, 3T3-L1 adipocytes, Min6 pancreatic β-cells 
and human embryonic kidney 293 cells to date, indicat-
ing that serum SelS is secreted by hepatocytes. In addi-
tion to the expression of SelS in the liver, skeletal muscle, 
adipose tissue, pancreatic islets and kidney, SelS was 
recently shown to be expressed in the vascular endothe-
lium and in vascular smooth muscle [5, 6]. However, 
whether SelS expression in the vascular endothelium and 
vascular smooth muscle is another source of secreted 
SelS is unknown. Transmembrane SelS is closely asso-
ciated with DM and AS, but the association of secreted 
SelS with DM and macroangiopathy remains unclear. 
Therefore, this study analyzed SelS levels in the super-
natants of vascular endothelial cells and vascular smooth 
muscle cells to investigate the source of serum SelS. Next, 
sera was collected from 158 human subjects to evalu-
ate the serum SelS detection conditions. Finally, the SelS 
levels in patients with T2DM and AS were compared to 




Construction of the SelS recombinant plasmid
The human SelS gene (GenBank: NM_018445.5) frag-
ment from the 104th to the 1205th nucleotide with a 
total length of 1102 bp was synthesized by Shanghai San-
gon Biotech Co., Ltd., China. BamHI and EcoRI restric-
tion enzyme sites were added at the 5′ and 3′ ends of 
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the fragment, respectively. Then, the SelS gene fragment 
and the pcDNA3.1(+) vector (5428  bp in length) were 
digested with EcoRI and BamHI and ligated using T4 
DNA ligase to construct the pcDNA3.1-SelS recombinant 
plasmid. After identification by restriction endonuclease 
analysis via agarose electrophoresis and sequencing, the 
pcDNA3.1-SelS recombinant plasmid was transiently 
transfected into cells using the Lipofectamine 2000 rea-
gent (Invitrogen, USA).
Cell culture and treatment
HUVECs, human aortic vascular smooth muscle cells 
(HA/VSMCs), and human hepatoma HepG2 cells were 
obtained from the American Type Culture Collec-
tion (ATCC, USA) and cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10  % fetal bovine 
serum, 100 U/ml of penicillin, and 100 μg/ml of strepto-
mycin in a humidified 5 % CO2 atmosphere at 37 °C.
The above three cell types were inoculated into 10 cm 
dishes. Each cell type was divided into three groups as 
follows: normal control group (NC) without transfec-
tion, pcDNA3.1 vector control group (pc-VC) with 
pcDNA3.1 empty vector transfection, and pcDNA3.1-
SelS group (pc-SelS) with pcDNA3.1-SelS recombinant 
plasmid transfection. The cells in the pc-VC and pc-SelS 
groups were transiently transfected with the correspond-
ing plasmids for 24  h. The cells in the NC group were 
incubated for 24  h without transfection. Then, the cells 
were washed three times with serum-free Dulbecco’s 
modified Eagle’s medium to remove dead cells and sub-
sequently cultured in 4  ml of serum-free Dulbecco’s 
modified Eagle’s medium for 24 h. The supernatants and 
cells in each group were carefully collected. The superna-
tants were centrifuged at 1000  rpm for 5  min and then 
transferred to ultrafiltration centrifuge tubes (Amicon® 
Ultra-4 Centrifugal Filter Devices, Millipore, USA) with 
a cutoff molecular weight of 3 kDa. After concentration, 
the supernatants were washed with phosphate-buffered 
saline and concentrated again to 100  µl (concentration 
fold was 4  ml/100  µl =  40-fold) for western blotting to 
detect secreted SelS. The collected cells were lysed, and 
the total protein was prepared for western blotting to 
evaluate endogenous SelS expression in the three cell 
types and SelS expression after pcDNA3.1 vector and 
pcDNA3.1-SelS transfection. The protein concentration 
was determined using a BCA protein assay kit (KeyGEN, 
China).
Western blotting analysis
A total of 30  μl of concentrated supernatant and cell 
lysates containing 30  µg of total protein were subjected 
to 12  % SDS–polyacrylamide gel electrophoresis and 
then transferred to polyvinylidene difluoride membranes 
(Millipore, USA). The polyvinylidene difluoride mem-
branes were blocked in phosphate-buffered saline and 
Tween 20 containing 5  % non-fat dry milk powder for 
1  h. Then, the membranes were incubated overnight 
at 4  °C with a rabbit anti-human SelS primary antibody 
(Abcam, USA) and subsequently incubated with a HRP-
labeled goat anti-rabbit secondary antibody (Thermo 
Fisher Scientific, USA) at 37 °C for 1 h. The protein bands 
were detected using an enhanced chemiluminescence 
detection kit (Thermo Fisher Scientific, USA) and ana-
lyzed using the Alpha chemiluminescence gel imaging 
system FluorChem FC3 (ProteinSimple, USA).
Human study
Subjects
The inclusion criteria for T2DM patients were as fol-
lows: patients aged between 40 and 70 years who met the 
World Health Organization criteria published in 1999 for 
the diagnosis and classification of DM.
The inclusion criteria for patients with AS and sub-
clinical AS (SAS) were as follows: (1) AS—patients aged 
between 40 and 70  years who showed evidence of car-
diovascular diseases (patients with histories of angina 
pectoris or myocardial infarction and a coronary CT 
angiography or coronary angiography showing coronary 
atherosclerotic plaques or stenosis), cerebrovascular dis-
eases (patients with histories of cerebral thrombosis or 
hypertension-induced cerebral hemorrhage confirmed by 
CT or MRI), and/or peripheral artery diseases (patients 
with intermittent claudication and arterial ultrasonog-
raphy of the bilateral lower limbs showing arterioscle-
rotic plaques or stenosis) and (2) SAS—patients aged 
40–70 years with no previous histories or present charac-
teristics of cardiovascular diseases, cerebral vascular dis-
eases or peripheral artery diseases but with intima media 
thickness values of the conducting arteries (common 
carotid artery or femoral artery) ≥1.0 mm and/or athero-
sclerotic plaques detected by ultrasonography.
The exclusion criteria were as follows: (1) acute dia-
betic complications within the previous 6  months; (2) 
renal or hepatic dysfunction; (3) acute or chronic infec-
tions within the previous 6  months; and (4) tumors or 
other chronic diseases.
This study selected 82 patients with T2DM hospital-
ized in the Department of Endocrinology of the First 
Affiliated Hospital of Dalian Medical University between 
October 2013 and December 2014. The patients were 
divided according to the presence of AS and SAS into 
the diabetes complicated with AS group (DAS, n = 29), 
the diabetes complicated with SAS group (DSAS, n = 29) 
and the isolated DM group (IDM, n = 24). Patients hos-
pitalized in the Department of Cardiology, Neurology, 
and Vascular Surgery of our hospital during the same 
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period who met the above AS inclusion criteria but did 
not have T2DM were recruited into the isolated AS 
group (IAS, n = 27). Patients who met the SAS inclusion 
criteria but did not have T2DM were included in the iso-
lated subclinical AS group (ISAS, n = 22) during physi-
cal examinations in our hospital during the same period. 
Additionally, 27 healthy subjects matched for age and 
gender with the above groups but without T2DM, AS, 
or SAS were selected to form the healthy control group 
(HC, n =  27) during physical examinations in our hos-
pital during the same period. The study was approved by 
the Ethics Committee of the First Affiliated Hospital of 
Dalian Medical University.
Clinical and laboratory examinations
Height, body weight and waist circumference (WC) 
measurements were obtained from all subjects and the 
corresponding body mass index (BMI) was calculated. 
Systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) at the resting state were measured twice 
continuously, and the mean values were calculated. Fast-
ing plasma glucose (FPG), glycosylated hemoglobin A1C 
(HbA1C), total cholesterol (TC), triglyceride (TG), high 
density lipoprotein cholesterol (HDL-C), and low density 
lipoprotein cholesterol (LDL-C) were measured using 
routine laboratory techniques. Serum samples were col-
lected and stored at −80  °C prior to use. Serum SelS 
levels were measured using an enzyme-linked immuno-
sorbent assay kit (Antibodies Online, USA) according to 
the manufacturer’s instructions. All samples were ana-
lyzed in triplicate.
The intima media thickness of the common carotid 
artery and the femoral artery were measured using a 
GE Logiq9 ultrasound performed by designated physi-
cians. The following locations were measured: (1) com-
mon carotid artery—the thickest location between 5 cm 
upstream and 5 cm downstream of the carotid bulb and 
(2) femoral artery—the thickest location within 10  cm 
upstream of the femoral artery bifurcation.
Statistical analysis
SPSS 17.0 software was used for the statistical analysis. 
Normally distributed quantitative data are presented as 
the mean ± standard deviation, and analysis of variance 
(ANOVA) in a factorial design was used for the com-
parison of clinical data among groups. Qualitative data 
are presented as frequencies, and the χ2 test was used for 
comparisons of percentages among groups. A compari-
son of SelS levels among the six groups was performed 
using ANOVA; the LSD method was performed after 
ANOVA for comparisons of the SelS levels between any 
two of the six groups. The interaction effect between AS 
and T2DM on the serum SelS level was assessed using 
ANOVA in a factorial design. The correlations of the 
serum SelS concentration with clinical variables were 
examined via Spearman bivariate correlation analysis. 
P < 0.05 was considered statistically significant.
Results
Verification of the pcDNA3.1‑SelS recombinant plasmid
The pcDNA3.1-SelS recombinant plasmid was verified 
by EcoRI/BamHI restriction endonuclease digestion 
and agarose gel electrophoresis (Fig. 1). The SelS cDNA 
sequence (Additional file 1: Figure S1) in the pcDNA3.1-
SelS recombinant plasmid was completely consistent 
with the sequence in GenBank (NM_018445.5). The 
results confirmed that the eukaryotic expression vector 
pcDNA3.1-SelS was constructed successfully.
Detection of SelS expression in HUVECs, HA/VSMCs, HepG2 
cell lysates and cell culture media
The western blot analysis showed that SelS was natu-
rally expressed in HUVECs, HA/VSMCs and HepG2 
cells. SelS expression was unchanged after pcDNA3.1 
empty vector transfection; however, its expression 
was increased after transfection of the pcDNA3.1-SelS 
recombinant plasmid into the above three cell lines. 
The concentrated cell culture media was analyzed using 
a western blot assay. Secreted SelS was only detected 
in the HepG2 cell supernatants. The secreted SelS level 
was unchanged after pcDNA3.1 empty vector trans-
fection but was increased after transfection of the 
Fig. 1 Restriction endonuclease analysis of the pcDNA3.1‑SelS 
recombinant plasmid. M, 1, and 2 represent the DNA ladder mix, 
pcDNA3.1, and pcDNA3.1‑SelS after EcoRI/BamHI restriction enzyme 
digestion, respectively
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pcDNA3.1-SelS recombinant plasmid into HepG2 cells. 
In contrast, secreted SelS was not detected in the culture 
media of HUVECs or HA/VSMCs even after transfection 
with the pcDNA3.1-SelS recombinant plasmid (Fig. 2).
Characteristics and comparisons of the clinical 
and laboratory variables among groups
WC, BMI, SBP, FPG, and TG were all higher in the 
T2DM group than in the non-T2DM group (subjects 
without T2DM) (P < 0.05). Age and SBP were higher in 
the SAS group than in the non-AS group (subjects with-
out AS) (P < 0.05). Age, WC, BMI, and SBP were higher 
in the AS group than in the non-AS group (P  <  0.05). 
WC, BMI, and TG were higher in the AS group than in 
the SAS group (P < 0.05) (Table 1).
Detection of serum SelS in all study subjects
Secreted SelS was detected in all serum samples from the 
158 study subjects with a detection rate of 100 %. The box 
plot showed that the minimum SelS level was 12.75 ng/dl, 
the maximum level was 118.67 ng/dl, and the mean level 
was 64.81  ng/dl among all serum samples. The overall 
serum SelS level in the study population showed a norm 
al distribution (Additional file 2: Figure S2A–B).
Comparisons of serum SelS levels among the six groups
The serum SelS level in the IDM group was lower than 
that in the HC group (52.66 ± 20.53 vs 70.40 ± 21.38 ng/
dl, P  =  0.005) (Fig.  3a). The serum SelS levels among 
the HC group, the ISAS group (59.26  ±  20.74  ng/dl) 
and the IAS group (61.83  ±  21.16  ng/dl) were not sig-
nificantly different (P  >  0.05) (Fig.  3a). The serum SelS 
levels were different in the three T2DM subgroups 
(P = 0.020) (Fig. 3a). The serum SelS levels in the DSAS 
group (67.73  ±  21.41  ng/dl, P  =  0.015) and the DAS 
group (71.69 ± 27.00 ng/dl, P = 0.002) were significantly 
increased compared with the IDM group, but there was 
no significant difference between the DAS and DSAS 
groups (P > 0.05). The interaction plot of T2DM and AS 
on serum SelS (Fig.  3b) showed that the SelS levels did 
not differ among the non-DM groups, including the HC 
group, the ISAS group and the IAS group. Therefore, we 
speculated that the SelS concentrations in these three 
groups had the same starting point. The serum SelS 
level was decreased in patients with T2DM alone; how-
ever, when T2DM was complicated with SAS or AS, the 
serum SelS levels were significantly increased compared 
with the IDM group, suggesting that there was a positive 
interaction effect between T2DM and AS on the serum 
SelS level (P = 0.002).
Spearman correlation analysis of the serum SelS 
concentration and clinical variables
A correlation analysis was performed on 51 study sub-
jects in the HC and IDM groups. The serum SelS concen-
tration was negatively correlated with WC (P  =  0.020) 
and FPG (P = 0.028) but was not significantly correlated 
with the other clinical indicators (Table 2).
Discussion
SelS is a transmembrane protein that is localized to 
the cell membrane and ER membrane [4, 10]. In 2013, 
Bubenik et al. [14] reported a new subcellular localization 
for SelS, i.e., enriched at perinuclear speckles of hepatoma 
HepG2 cells. The authors co-stained HepG2 cells for SelS 
(green fluorescence) and a Golgi marker (golgin p97, red 
fluorescence) and showed a partial overlap between the 
two proteins (yellow fluorescence), suggesting that part of 
the perinuclear aggregated SelS was localized in the Golgi 
apparatus. In addition to its intracellular localization, SelS 
was also detected in the supernatant of HepG2 cells and 
human serum by Gao et al. [1]. The authors demonstrated 
that this secreted SelS was full length and was not pro-
teolytically processed prior to secretion by HepG2 cells. 
Protein secretion by the majority of eukaryotic cells is 
achieved through the typical ER-Golgi secretory pathway 
Fig. 2 Detection of SelS in HUVEC, HA/VSMC, and HepG2 cell lysates and concentrated cell supernatants by western blotting. 1, 2, and 3 represent 
the normal control group NC without transfection, pcDNA3.1 vector control group pc-VC with pcDNA3.1 empty vector transfection, and pcDNA3.1‑
SelS group pc-SelS with pcDNA3.1‑SelS recombinant plasmid transfection, respectively
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[15]. Gao et al. [1] showed that SelS secretion was com-
pletely abolished after pretreatment of HepG2 cells with 
Brefeldin A (a well-known and specific ER-Golgi transport 
inhibitor). Combined with the endoplasmic reticulum and 
Golgi localization of SelS mentioned above [4, 14], these 
results indicated that the secretion of SelS by HepG2 cells 
was achieved through the endoplasmic reticulum-Golgi 
route. Gao et al. [1] demonstrated that SelS was secreted 
by hepatocytes but not L6 skeletal muscle cells, 3T3-L1 
adipocytes, Min6 pancreatic β-cells and human embry-
onic kidney 293 cells. SelS was recently demonstrated to 
be expressed in the vascular endothelium and vascular 
smooth muscle in addition to the liver, skeletal muscle, 
adipose tissue, pancreatic islets and kidney [5, 6]. Because 
Table 1 Clinical and laboratory characteristics of the study population
HC, ISAS, IAS, IDM, DSAS, and DAS represent the healthy control group, the isolated subclinical AS group, the isolated AS group, the isolated DM group, the diabetes 
complicated with SAS group and the diabetes complicated with AS group, respectively
a significantly different among non-AS, SAS, and AS at P < 0.05 based on ANOVA
b significantly different within groups between SAS and non-AS at P < 0.05 based on the LSD method after ANOVA
c significantly different within groups between AS and non-AS at P < 0.05 based on the LSD method after ANOVA
d significantly different within groups between SAS and AS at P < 0.05 based on the LSD method after ANOVA
e significantly different between subjects with and without T2DM
Group Gender Agea, b, c WCa, c, d, e BMIa, c, d, e SBPa, b, c, e DBP
(Male/female) (years) (cm) (kg/m2) (mmHg) (mmHg)
HC 27 (6/21) 56.22 ± 5.65 84.69 ± 9.98 24.16 ± 2.50 119.85 ± 13.56 77.44 ± 7.59
ISAS 22 (9/13) 56.73 ± 7.52 83.92 ± 10.44 24.64 ± 2.61 129.05 ± 12.67 80.14 ± 9.14
IAS 27 (13/14) 56.52 ± 6.72 87.13 ± 6.77 25.98 ± 2.67 129.07 ± 14.80 80.44 ± 6.91
IDM 24 (12/12) 49.71 ± 5.03 94.00 ± 9.03 26.91 ± 3.54 129.58 ± 17.32 81.25 ± 10.03
DSAS 29 (14/15) 58.17 ± 7.87 93.57 ± 10.01 26.14 ± 3.62 138.41 ± 17.39 81.00 ± 8.78
DAS 29 (14/15) 61.48 ± 7.88 98.28 ± 6.84 26.77 ± 2.93 141.10 ± 15.65 79.93 ± 8.56
Group HbA1c FPGe Sqrt (TG)a, d, e TC LDL‑C HDL‑C
(%) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L)
HC – 5.37 ± 0.43 1.29 ± 0.40 5.45 ± 0.85 3.11 ± 0.63 1.29 ± 0.20
ISAS – 5.23 ± 0.16 1.21 ± 0.24 5.02 ± 0.89 2.81 ± 0.48 1.21 ± 0.20
IAS – 5.16 ± 0.40 1.23 ± 0.25 4.46 ± 1.15 2.54 ± 0.85 1.10 ± 0.27
IDM 8.42 ± 1.65 8.64 ± 2.85 1.38 ± 0.32 4.84 ± 1.20 2.72 ± 0.75 1.19 ± 0.30
DSAS 9.14 ± 1.89 7.90 ± 2.07 1.15 ± 0.25 4.51 ± 0.73 2.57 ± 0.56 1.12 ± 0.17
DAS 9.05 ± 1.42 9.32 ± 3.56 1.36 ± 0.46 5.07 ± 1.18 2.93 ± 0.82 1.23 ± 0.29
Fig. 3 Serum SelS levels in different groups (a) and the interaction of AS and T2DM on the serum SelS concentration (b). HC, ISAS, IAS, IDM, DSAS, 
and DAS represent the healthy control group, the isolated subclinical AS group, the isolated AS group, the isolated DM group, the diabetes compli‑
cated with SAS group and the diabetes complicated with AS group, respectively. Values are expressed as the mean ± SD. *P < 0.01 compared to HC; 
#P < 0.05 and ##P < 0.01 compared to IDM
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HUVECs and VSMCs were suggested to be capable of 
secreting a number of proteins associated with biological 
functions, such as cell proliferation, cell differentiation, 
cell adhesion, and cell signaling [16–19], we used these 
two cell types as model systems to investigate whether 
they could be another source of secreted SelS. This study 
showed that secreted SelS was not detected in the super-
natants of naturally cultured HUVECs and HA/VSMCs, 
even after transfection with the pcDNA3.1-SelS recombi-
nant plasmid. SelS was only detected in the supernatants 
of naturally cultured HepG2 cells, and the secreted SelS 
level increased after transfection with the pcDNA3.1-
SelS recombinant plasmid. These results revealed that the 
vascular endothelium and vascular smooth muscle cells 
did not secrete SelS and that serum SelS was primarily 
secreted by hepatocytes.
Gao et  al. [1] analyzed 209 human serum samples via 
ELISA. SelS was detected in 65 out of 209 human serum 
samples, for a detection rate of 31.3  %; the mean SelS 
level was 15.7 ng/mL [1]. In this study, we analyzed 158 
human serum samples and detected SelS in all of them, 
for a detection rate of 100 %. The mean serum SelS level 
was 64.81 ng/dl. The overall serum SelS level in the study 
population showed a normal distribution. Differences in 
the race and region of the human subjects used in Gao’s 
study and ours might have contributed to the incon-
sistent results. The human subjects in Gao’s study were 
Caucasian (the white race) while in our study were Mon-
goloid (the yellow race). Additionally, the primary SelS 
antibody and SelS standard solution used in ELISA assay 
was created by Gao et al. [1] themselves while the ELISA 
assay kits used in our study were commercially avail-
able and relatively mature in technology, which might be 
another reason for the inconsistent results.
Hepatic SelS was closely associated with body glucose 
metabolism. Hepatic SelS expression in Psammomys 
obesus with impaired glucose tolerance and T2DM 
was lower than that in Psammomys obesus with nor-
mal glucose tolerance [2], and HepG2 SelS expression 
was suppressed by glucose in a dose-dependent man-
ner in vitro [3]. The association between serum SelS and 
glucose metabolism was first analyzed by Gao et al. [1]. 
These authors detected and compared serum SelS lev-
els in healthy individuals (41.7  %, 27.8  ng/ml), type 1 
DM patients (23.2  %, 34.0  ng/ml), and T2DM patients 
(27.9 %, 34.3 ng/ml) and found that the average SelS level 
among these three groups did not differ significantly. In 
this study, we demonstrated that the serum SelS level in 
isolated T2DM patients was lower than that in healthy 
subjects and was negatively correlated with the fasting 
plasma glucose concentration. This finding was consist-
ent with the aforementioned changes in hepatic SelS 
expression and HepG2 cells, indicating that serum SelS 
was secreted by hepatocytes. Gao et  al. [11] found that 
SelS overexpression in hepatoma H4IIE cells reduced 
basal and insulin-stimulated hepatic glucose utilization 
and that this effect was even more evident under insulin 
stimulation. Additionally, the authors showed that SelS 
overexpression antagonized the inhibitory effect of insu-
lin on phosphoenolpyruvate carboxykinase, which is a 
rate-limiting enzyme in the hepatic gluconeogenesis pro-
cess, thereby increasing the hepatic glucose output. As 
a result, the reduction in the serum SelS level in T2DM 
patients in our study might be a body defense response to 
relieve the high glucose status and increase insulin sensi-
tivity. These results suggest that reducing the hepatic and 
serum SelS levels might become a strategy for the pre-
vention and treatment of T2DM.
SelS belongs to the selenoprotein family, which consists 
of glutathione peroxidases or thioredoxin reductases that 
contain one selenocysteine [20, 21]. Glutathione peroxi-
dase activity was markedly augmented in rodent models 
with both diabetes and myocardial infarction compared 
to diabetes or myocardial infarction alone [22]. Moreover, 
pro-angiogenic cells were reported to exhibit lower levels 
of cytoprotective genes, including glutathione peroxidase 
[23]. These results indicate that SelS may be involved in 
the pathogenesis and development of diabetic macroan-
giopathy. However, an association between hepatic SelS 
and macroangiopathy has not been reported to date. In 
this study, we analyzed the association between serum 
SelS with AS and DM complicated with AS and showed 
that the serum SelS levels in the T2DM patients with SAS 
or AS did not differ from the level in healthy individu-
als. Intriguingly, among the T2DM groups, the serum 
SelS levels in the patients with DSAS or DAS were sig-
nificantly higher than the level in T2DM patients. Addi-
tionally, there was a positive interaction effect between 
T2DM and AS on the serum SelS level. These results 
Table 2 Spearman correlation analysis between the serum 
SelS concentration and clinical variables
* P < 0.05
Clinical variables r P
Age (years) 0.204 0.151
WC (cm) −0.324 0.020*
BMI (kg/m2) −0.140 0.328
SBP (mmHg) −0.158 0.269
DBP (mmHg) −0.135 0.344
FPG (mmol/L) −0.269 0.028*
TG (mmol/L) −0.207 0.145
TC (mmol/L) −0.071 0.621
LDL‑C (mmol/L) −0.050 0.729
HDL‑C (mmol/L) −0.115 0.421
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indicate that serum SelS might be involved in the patho-
genesis and development of AS in T2DM patients and 
indirectly suggest that hepatic SelS might be associated 
with AS. However, the association between hepatic SelS 
and diabetic macroangiopathy requires further investi-
gation. Recently, Cox et al. [24] analyzed the association 
between 10 single nucleotide polymorphisms (SNPs) in 
the SelS gene with the risk for AS and subclinical AS by 
examining 1220 European-Americans from the Diabe-
tes Heart Study. The authors found that the SelS SNPs 
rs28665122, rs4965814, rs28628459, rs7178239, and 
rs12917258 were associated with subclinical AS, whereas 
the SelS SNPs rs4965814, rs28628459, and rs9806366 
were associated with AS. The studies conducted by Cox 
et al. [24] and our group suggest a potential role for SelS 
gene polymorphisms in predicting the occurrence of 
macrovascular complications in T2DM patients. Thus, 
reducing liver and serum SelS levels may become new 
interventions for the prevention and treatment of dia-
betic macroangiopathy.
Serum amyloid A can interact with SelS; this interac-
tion has been confirmed by a yeast 2-hybrid screen and 
surface plasmon resonance analysis [2]. Additionally, 
serum amyloid A is a risk factor for the occurrence of 
macroangiopathy in T2DM patients [25]. Therefore, we 
speculated that serum amyloid A might be related to 
the involvement of SelS in the pathogenesis of diabetic 
macroangiopathy. Furthermore, a NF-κB binding site 
is located within the SelS gene promoter [4]. Thus, as a 
target of NF-κB, SelS might participate in the occurrence 
and development of diabetic macroangiopathy through 
the NF-κB signaling pathway. However, the function 
of hepatic and serum SelS in DM and AS as well as the 
underlying mechanisms requires validation in animal 
models and warrants further investigation.
Study limitations
There are several limitations in our study. First, we and 
Gao et  al. [1] performed in  vitro detections of whether 
the cells of corresponding tissues could secrete SelS 
according to the histological distribution of SelS. The 
results showed that SelS was not secreted by adipocytes, 
skeletal muscle cells, human embryonic kidney cells, pan-
creatic islet β cells, vascular endothelial cells, and vascu-
lar smooth muscle cells but was secreted by hepatocytes. 
Thus, we concluded that serum SelS was secreted from 
the liver. However, whether serum SelS is solely secreted 
from the liver remains unclear, and further studies using 
animal models with selective knockout of the hepatic 
SelS gene are required. Next, this study was retrospec-
tive; therefore, we could only investigate whether serum 
SelS was associated with T2DM and its macrovascular 
complications rather than draw a conclusion regarding 
the causal relationship between these two factors. Finally, 
the sample size in the present study was limited, and this 
study could be regarded as a preliminary study. There-
fore, our results require further validation in a prospec-
tive randomized controlled trial with a larger sample size.
Conclusions
Vascular endothelial cells and vascular smooth muscle 
cells did not secrete SelS, and serum SelS was primarily 
secreted by hepatocytes. SelS was universally detected 
in human serum samples, and the serum SelS level was 
associated with T2DM and its macrovascular complica-
tions. The reduction of liver and serum SelS levels may 
become a new target for the prevention and treatment of 
T2DM and its macrovascular complications.
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